TwoStep

Oncology Therapeutics
1Open roles
Lately:7 news stories in 90 daysFollow changes →

Facts

as of Nov 19, 2026

TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.

It is hiring: 1 open role, 0 of them posted in the last 30 days.

Headquarters
San Francisco, United States
Employees
11-50estimated range
Open roles
1Alion job postings

As of Nov 19, 2026, Alion lists 1 open role at TwoStep. TwoStep is headquartered in San Francisco, United States.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Hiring slowly: few roles were posted lately.

Management is the largest family, 100 of open roles.

0%Remote roles0 of 1
1Hiring offices
Alion signals0-100
Demand18
Pay10
Your chance46
How badly they need people, whether they pay, how realistic getting in is.
Where the openings areshare of open roles · trend
Management100▼
Benefits named in postingsshare of open roles
Equity1100%
Life insurance1100%
Contract type
Full-Time 1
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
San FranciscoBusiest site
SiteTypeOpen rolesHires most forEngineering
San Francisco United StatesHeadquarters1Management0%
Source: office addresses in postings and company registers

Milestones

Mar 2024
Each milestone is dated by its source: registers, filings, the press

Newsroom

Sep 272026
News · noteノート
Since the global blockbuster success of Daiichi Sankyo's Enhertu, the world of biotech investment has been buzzing with an unprecedented 'ADC boom.' However, behind that frenzy,…
Sources: the outlets named on each headline, each story once